Ipsen Pharma S.a.s.

Repligen Corporation

Jundong Zhang

Zheng Xin Dong

Sun H Kim

Christophe Thurieau

Michael DeWitt Culler

James R Rusche

Yeelana Shen

Jeanne Mary Comstock

Deborah M Rothman

Nicholas C Prairie

Maria L Ufret

Deborah Rothman

Sun Hyuk Kim

Christophe Alain Thurieau

The present invention relates to improvements in compositions containing peptides that are ligands of one or more of the melanocortin receptors (MC-R), or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NHwhich is a ligand of the melanocortin receptor subtype 4 (MC4-R), and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms a depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol (PEG) with an average molecular weight of lower than 1000.

Pharmaceutical compositions of melanocortin receptor ligands

The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues of IGF-1 having an amino acid substitution at position 59, e.g., (Asn)hIGF-1(1-70)-OH (SEQ ID NO:1), and other substitution(s) as defined herein.

Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59

The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.

Peptide-cytotoxic conjugates

The invention is based on the discovery that the levels of one or more methylxanthines in urine samples are significantly decreased in children diagnosed with symptoms of autistic disorder, compared to the levels in normal children, and that levels of xanthines in urine are increased in autistic children. Consequently, the presence in the urine of levels of methylxanthines below a certain range and the level of xanthine above a certain range, are diagnostic of autistic disorder. In another aspect, one or more of these methylxanthines can be used to treat individuals exhibiting symptoms of autistic disorder.

Methylxanthines in the diagnosis and treatment of autistic disorder

Growing community of inventors

Newton, MA, United States of America

Jundong Zhang